Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Hauls in $6.6M in Venture Funding

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said today that it has raised €4.5 million ($6.6 million) through investments from VC Fonds Berlin, the ERP Startfonds, and from other private investors.
The company plans to use the money to develop and sell its CCMS proteomics analysis technology, which uses tri-functional molecules called capture compounds and complements 2D gel electrophoresis and affinity chromatography. The capture compounds serve as chemical probes by detecting proteins directly in solutions, the company said.
The startup plans to initiate operations by moving into new facilities in Berlin-Adlershof and staffing up. Caprotec also will begin developing kits for proteomics R&D and for drug and biomarker development.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.